NK cells engineered for a chimeric form of an activating receptor such as DNAM-1 are likely to specifically target tumor cells which express high levels of PVR and Nectin-2 (Figure 1), while should be tolerant of normal cells expressing low levels of PVR and Nectin-2 [protein.atlas.org, GTEx from TCGA database and (4)]. The gene discussed is NECTIN2; the disease is neoplasm.